Simcere Pharmaceutical Group Limited

Dec 04, 2024

China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke

Oct 30, 2024

World Stroke Congress | TASTE-2 significantly reduces stroke disability

Oct 25, 2024

TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability

Sep 14, 2024

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Sep 02, 2024

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Feb 20, 2024

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA